Larry L. Augsburger, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Larry L. Augsburger, PhD


Larry L. Augsburger, PhD, is a Pharmtech editorial advisory board (EAB) member

Larry L. Augsburger, PhD
Professor, Department of
Pharmaceutics
University of Maryland

Augsburger is an emeritus professor at the University of Maryland School of Pharmacy. He previously served as the Shangraw Professor of Industrial Pharmacy and Pharmaceutics, chair of the department of pharmaceutics and director of pharmaceutics graduate programs. He has overseen graduate and postdoctoral student research in the areas of design and optimization of immediate release and extended release oral solid dosage forms, the functionality of excipients, the instrumentation of pharmaceutical processing equipment, and botanical dietary supplement product development and quality.

Augsburger established the Drug Development Facility in the school of pharmacy, which later became UPM Pharmaceuticals, Inc., a university-affiliated for-profit firm for developing drugs and manufacturing clinical supplies. A founding father of UPM, he served for five years as its vice-president of pharmaceutical development and manufacture.

He was a principal investigator and directed the research programs of the $12-million University of Maryland-FDA Collaborative Agreements that led to the development of SUPAC regulatory policies for immediate- and modified-release oral solid dosage forms. Augsburger is an elected fellow and former president of the American Association of Pharmaceutical Scientists (AAPS). Among his awards are the Federation Internationale Pharmaceutique (FIP) Industrial Pharmacy medal, the FDA Commissioner's Special Citation, the AAPS Research Achievement Award and the AAPS Outstanding Educator Award.

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search

Click here